Physician profile
Stanford W Downs
NPI 1801808969
$18,809.85
in general payments reported to CMS, 2019-2025
61 companies · $3,929 in 2025
The $3,929 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,639 · 2020: $1,022 · 2021: $1,592 · 2022: $2,744 · 2023: $3,222 · 2024: $3,662 · 2025: $3,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,601.65 |
| Education | $210.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $2,235.46 | 2019-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $1,429.46 | 2021-2025 | Ubrelvy, Qulipta |
| Neurocrine Biosciences, INC. | $1,387.38 | 2019-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $1,373.05 | 2020-2025 | Fintepla, Rystiggo, Briviact |
| Biogen, INC. | $1,155.21 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Alexion Pharmaceuticals, INC. | $793.12 | 2019-2025 | Ultomiris, Soliris, Koselugo |
| Sk Life Science, INC. | $760.61 | 2021-2025 | Xcopri |
| Novartis Pharmaceuticals Corporation | $707.89 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $703.66 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Tg Therapeutics, INC. | $635.26 | 2023-2025 | |
| Amgen INC. | $615.10 | 2019-2025 | Uplizna |
| Genzyme Corporation | $576.51 | 2019-2025 | |
| Celgene Corporation | $483.86 | 2019-2025 | Zeposia |
| Neurelis, INC. | $469.98 | 2021-2025 | Valtoco |
| Lundbeck LLC | $458.09 | 2022-2025 | Vyepti, Rexulti |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanford Downs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.